In recent times, the Zomedica Corp (NYSEAMERICAN:ZOM) stock has been in considerable focus among many investors and in this regard, it should be noted that the stock has now slumped below the $1 a share mark.
The launch of its pet diagnostic platform Truforma was a key event and that had driven a certain degree of optimism about Zomedica among investors. Around two months ago, the stock was trading over $2 a share and hence, it is a penny stock that could be worth tracking.
The most important thing that is expected to drive any kind of growth for Zomedica is its sales. The company may continue to record losses but if it manages to record considerable sales then it might get the advantage of scale that might lead to the creation of new animal diagnostic products. In that way, Zomedica might end up becoming a full-service animal healthcare company and eventually drive considerable value for its shareholders.
Biotech, Tech, and Crypto reporter
Anthony Gonzales brings 3 years of experience in helping grassroots, mid-sized organizations and large institutions strengthen their management and resource generating capacities and effectively plan for the future. He is also a mentor and professional advisor to artists working in all disciplines. He is the gold medalist from St. Marco University of Science and Technology in the Bachelors of Financial Management as well.